Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target Cut to $8.00 by Analysts at Needham & Company LLC

Recursion Pharmaceuticals (NASDAQ:RXRX - Free Report) had its price objective lowered by Needham & Company LLC from $11.00 to $8.00 in a research note published on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities research analysts also recently weighed in on the company. Leerink Partners cut their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Morgan Stanley dropped their price objective on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. KeyCorp decreased their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th. Finally, Cowen reiterated a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of "Hold" and an average price target of $7.60.

Recursion Pharmaceuticals Stock Performance

RXRX stock traded down $0.06 during trading on Tuesday, reaching $4.33. 14,766,105 shares of the company's stock were exchanged, compared to its average volume of 12,910,924. The firm has a market cap of $1.74 billion, a PE ratio of -2.83 and a beta of 0.99. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals has a 1-year low of $3.79 and a 1-year high of $12.36. The company's fifty day moving average price is $5.53 and its 200-day moving average price is $6.66.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $14.75 million during the quarter, compared to analyst estimates of $18.12 million. During the same period in the previous year, the company earned ($0.39) EPS. The business's revenue for the quarter was up 7.2% compared to the same quarter last year. On average, research analysts expect that Recursion Pharmaceuticals will post -1.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Barclays PLC raised its stake in shares of Recursion Pharmaceuticals by 53.9% during the 3rd quarter. Barclays PLC now owns 697,432 shares of the company's stock worth $4,596,000 after purchasing an additional 244,278 shares in the last quarter. JPMorgan Chase & Co. grew its position in Recursion Pharmaceuticals by 6.1% in the third quarter. JPMorgan Chase & Co. now owns 1,176,191 shares of the company's stock worth $7,751,000 after acquiring an additional 67,464 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Recursion Pharmaceuticals by 1,979.2% during the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock worth $35,000 after purchasing an additional 4,948 shares during the last quarter. Green Alpha Advisors LLC lifted its stake in shares of Recursion Pharmaceuticals by 3.6% in the 4th quarter. Green Alpha Advisors LLC now owns 67,145 shares of the company's stock valued at $454,000 after purchasing an additional 2,346 shares during the last quarter. Finally, DBK Financial Counsel LLC bought a new stake in Recursion Pharmaceuticals in the fourth quarter worth $101,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.